1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,760 | 2,920 | 18.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| Mi | GENFLEET-B (02595): 2026 INTERIM REPORT | 1 | HKEx | ||
| Di | GENFLEET-B Says GFH375 Achieves 59.2% ORR in Phase II Study for Previously Treated NSCLC | 1 | AASTOCKS | ||
| Di | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FAVORABLE PHASE II EFFICACY DATA OF GFH375 (ORAL KRAS G12D INHIBITOR) MONOTHERAPY IN PRETREATED NSCLC PRESENTED ... | 1 | HKEx | ||
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.09. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 02.09. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 26.08. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375, ORAL KRAS G12D INHIBITOR, ADVANCES INTO A PHASE II STUDY EVALUATING MONOTHERAPY AND COMBINATION REGIMENS ... | 1 | HKEx | ||
| 21.08. | GENFLEET-B Interim Loss Narrows to RMB220 million | 1 | AASTOCKS | ||
| 21.08. | GENFLEET-B (02595): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 20.08. | GENFLEET-B Initiates Phase II Study for Two Pancreatic Cancer Combination Therapies of GFH375 | 1 | AASTOCKS | ||
| 20.08. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 ADVANCES INTO A NOVEL PHASE II STUDY FEATURING TWO FIRST-IN-WORLD COMBINATION THERAPIES FOR PANCREATIC ... | 2 | HKEx | ||
| 10.08. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT WORLD'S FIRST REGISTRATIONAL PHASE III STUDY FOR ORAL KRAS G12D INHIBITOR IN NSCLC ADVANCES, AS FIRST PATIENT ... | 1 | HKEx | ||
| 06.08. | GENFLEET-B (02595): DATE OF BOARD MEETING | 1 | HKEx | ||
| 17.07. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 17.07. | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 17.07. | GENFLEET-B (02595): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 15.07. | GENFLEET-B (02595): PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 29.06. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PROPOSED SHARE REPURCHASE ON THE MARKET | 2 | HKEx | ||
| 02.06. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 MONOTHERAPY DATA PRESENTED AT 2026 ASCO ORAL SESSION: WORLD'S FIRST DEDICATED DATA OF A RAS INHIBITOR ... | 1 | HKEx | ||
| 01.06. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PRELIMINARY PHASE I DATA OF GFS202A FOR CACHEXIA PRESENTED IN POSTER SESSION OF 2026 ASCO ANNUAL MEETING, FEATURING ... | 1 | HKEx |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| ELECTRA THERAPEUTICS | 13,500 | +1,89 % | Electra Therapeutics, Inc.: Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines... ► Artikel lesen | |
| CABALETTA BIO | 2,550 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 299,28 | +0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,850 | 0,00 % | Candel Therapeutics auf der H.C. Wainwright Konferenz: Fokus auf Prostatakrebs-Therapie | ||
| COGENT BIOSCIENCES | 31,480 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,80 | +0,04 % | Kymera Therapeutics auf Morgan Stanley Konferenz: Offensive bei oralen Degradern |
Das Unternehmen GENFLEET THERAPEUTICS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,821 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.